532488

Divi's Laboratories reported strong Q4 and FY26 performance. Management anticipates double-digit revenue growth for the future, with margins expected to remain stable despite competitive pricing and raw material cost pressures. The company capitalized ₹2,500 crores in FY26 (₹800 crores in Q4) and has ₹2,113 crores in capital work in progress, with revenue from capex expected within 2 years. Supply chain disruptions and increased freight costs due to geopolitical tensions were successfully managed, ensuring supply reliability. Growth drivers include a strong project pipeline in custom synthesis, deepening capabilities in peptides with validated fragments, and commercial sales in iodine-based contrast media. Exports constitute 89% of revenue, benefiting from currency depreciation. Divi's aims to be a leading global player in the peptide segment.

Consolidated Revenue ₹2831Cr vs ₹2585Cr (▲10% YoY), EBITDA ₹934Cr vs ₹886Cr (▲5% YoY), PAT ₹751Cr vs ₹662Cr (▲13% YoY). EBITDA Margin 33% vs 34% (▼128bps). The company also recommended a final dividend of ₹30/- per equity share for FY 2025-26.

Divi's Laboratories Limited announced the upload of the audio recording for its Q4 FY26 earnings conference call, held on May 23, 2026, at 14:30 Hrs. (IST), to the Investors Relations section of their website.

Consolidated Revenue ₹2,831Cr vs ₹2,585Cr (▲9.5% YoY), EBITDA ₹1,089Cr vs ₹972Cr (▲12.0% YoY), PAT ₹751Cr vs ₹662Cr (▲13.4% YoY). EBITDA Margin 38.5% vs 37.6% (▲90bps). A final dividend of ₹30/- per equity share was recommended for the financial year 2025-26, subject to shareholder approval.

Divi's Laboratories Limited announced its Consolidated Q4 FY2026 results. Consolidated Revenue was ₹2,831Cr vs ₹2,585Cr (▲10% YoY), EBITDA was ₹934Cr vs ₹886Cr (▲5% YoY), and PAT was ₹751Cr vs ₹662Cr (▲13% YoY). EBITDA Margin was 33% vs 34% (▼128bps). The company also recommended a final dividend of ₹30/- per equity share for FY2025-26.

Divi's Laboratories Limited reported Consolidated Revenue of ₹2,831 Cr vs ₹2,585 Cr (▲9.5% YoY), EBITDA of ₹934 Cr vs ₹886 Cr (▲5.4% YoY), and PAT of ₹751 Cr vs ₹662 Cr (▲13.4% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 33.0% vs 34.3% (▼130bps). The Board also recommended a final dividend of ₹30/- per equity share for FY 2025-26.

Divi's Laboratories Limited announced that its audited financial results for the quarter and year ended March 31, 2026 (Q4FY26), will be released on May 23, 2026. Following the release, the company will host an earnings conference call on the same day at 14:30 hrs (IST) to discuss its financial performance.

Divi's Laboratories Limited announced that its Board of Directors will meet on May 23, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend for the financial year 2025-26. The trading window for dealing in securities of the company will remain closed until May 25, 2026.

Divi's Laboratories Limited announced the closure of its trading window from April 01, 2026, until 48 hours after the declaration of audited financial results for the quarter and financial year ended March 31, 2026. The Board meeting date will be intimated subsequently.

Divi's Laboratories received a Draft Order from the Income Tax Authority for FY2022-23, proposing additions/disallowances of ₹570.51 crores related to Transfer Pricing and corporate tax adjustments, potentially leading to additional tax liability and penalty. The company plans to appeal.

Divi's Laboratories submitted the transcript of its Q3FY2026 earnings conference call for the quarter and nine months ended December 31, 2025. Key updates included stable performance in Generics, healthy performance in Nutraceuticals, and a successful FDA inspection. An exceptional item of ₹74 crore was reported due to new labor codes.

New Filing detected. See link for details.

Divi's Laboratories Limited announced the audio recording of its Q3FY26 earnings conference call, held on February 11, 2026, for the quarter ended December 31, 2025, has been uploaded on its website.

New Filing detected. See link for details.